Intercell is pleased to announce that the U.S. Food and Drug Administration (FDA) approved IXIARO®, a new vaccine for the prevention of Japanese Encephalitis (JE). With the approval of IXIARO® by the FDA, Intercell is one of the very few Biotech companies to get a consumer vaccine approved.

We cordially invite you to take part in our Analyst and Media Call on

03:00 pm CET
02:00 pm GMT
09:00 am EST

Please click on the links below to download to download the presentation and the press release:

• Presentation Analyst and Media Call – U.S. approval for IXIARO® (pdf, 1.3MB)
• Press release: Intercell Announces FDA Approval of IXIARO®, a Novel Vaccine to Prevent Japanese Encephalitis (pdf, 194kB)

Chairpersons: Gerd Zettlmeissl (CEO) and Thomas Lingelbach (COO and Managing Director Intercell Biomedical Ltd., Scotland). 

Dial-In: 
Austria: +43 (0)2682 205 62 92
UK: +44 (0)20 7131 2799
US: +1 334 323 62 01
Germany: +49 (0)69 589 990 507
Switzerland: +41 (0)434 56 92 61

Please quote "Intercell Call" and an operator will then put you through to the Intercell conference call.

Download conference call

• Recording (.mp3, 2.1M)